1. Home
  2. CNTN vs TNXP Comparison

CNTN vs TNXP Comparison

Compare CNTN & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CNTN

Canton Strategic Holdings Inc. Common Stock

N/A

Current Price

$3.58

Market Cap

185.3M

Sector

Health Care

ML Signal

N/A

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$12.97

Market Cap

198.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNTN
TNXP
Founded
2017
2007
Country
United States
United States
Employees
12
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.3M
198.6M
IPO Year
2022
2008

Fundamental Metrics

Financial Performance
Metric
CNTN
TNXP
Price
$3.58
$12.97
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
441.5K
363.1K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.75
EPS
N/A
N/A
Revenue
N/A
$13,107,000.00
Revenue This Year
N/A
$558.11
Revenue Next Year
N/A
$38.29
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.85
52 Week Low
$2.89
$11.60
52 Week High
$5.27
$69.65

Technical Indicators

Market Signals
Indicator
CNTN
TNXP
Relative Strength Index (RSI) 55.74 45.53
Support Level $3.01 $12.43
Resistance Level $3.82 $14.85
Average True Range (ATR) 0.24 1.16
MACD 0.04 -0.02
Stochastic Oscillator 69.47 14.73

Price Performance

Historical Comparison
CNTN
TNXP

About CNTN Canton Strategic Holdings Inc. Common Stock

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: